Related Experiment Video

Updated: Aug 18, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents

Ken Sato1, Yoshihiko Kitajima, Naohiko Kohya

  • 1Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.

International Journal of Oncology
|May 5, 2005
PubMed

Insights

Gallbladder cancer cells lacking O6-methylguanine methyltransferase (MGMT) and expressing hMLH1 showed the highest sensitivity to alkylating agents like MNU and DTIC. This suggests MGMT and hMLH1 status can guide chemotherapy selection for gallbladder carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Gallbladder carcinoma is often treated with alkylating agents.
  • Predicting patient response to chemotherapy remains a challenge.

Purpose of the Study:

  • To determine if O6-methylguanine methyltransferase (MGMT) and hMLH1 expression predict sensitivity to alkylating agents in gallbladder cancer.
  • To investigate the molecular mechanisms of drug sensitivity related to MGMT and hMLH1 status.

Main Methods:

  • Analyzed MGMT and hMLH1 expression in gallbladder and colon cancer cell lines using RT-PCR and Western blotting.
  • Assessed drug sensitivity to N-methyl-N-nitrosourea (MNU) and dacarbazine (DTIC).
  • Performed flow cytometry to analyze cell cycle arrest and measured cyclin A and Cdc2 expression.

Main Results:

  • Cell lines with low MGMT and high hMLH1 (MGMT-/hMLH1+) exhibited the highest sensitivity to both MNU and DTIC.
  • MNU induced G2-M cell cycle arrest and reduced cyclin A and Cdc2 expression in sensitive cells (MGMT-/hMLH1+).
  • Resistant cells (MGMT+/hMLH1+ or MGMT-/hMLH1-) did not show these effects.

Conclusions:

  • Combined MGMT and hMLH1 status can predict sensitivity to monofunctional alkylating agents in gallbladder carcinoma.
  • MGMT-/hMLH1+ status is associated with MNU-induced G2-M cell cycle arrest and proliferation suppression.
  • These biomarkers may help select patients for alkylating agent chemotherapy.

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...